MAUDE MDR 8523258

MDR report key
8523258
Report number
9610200-2019-00004
Event key
0
Event type
3
Date of event
2019-03-24
Date received
2019-04-17
Adverse event
3
Product problem
0
Patients in event
0
Reporter occupation
0
Health professional
0
Initial report to FDA
0
Event location
3

Manufacturer Contact#

Contact
MR GIUSEPPE DI SANTE
Address
VIA PONTE DELLA FABBRICA, 3/A ABANO TERME, PADUA 35031 IT
Report source
M
Manufacturer link flag
Y

Devices#

Seq, Brand, Generic table
SeqBrandGenericManufacturerProduct codeModelCatalogLotPMA510(k)ImplantEvaluatedAvailability
1HYALOGYNHYALOGYN VAGINAL HYDRATING GELFIDIA FARMACEUTICI S.P.A.NUC179604UNKR N

Patients#

Sequence, Received, Treatment table
SequenceReceivedTreatmentOutcome
12019-04-1701. O

Event Narratives#

N

Patient 1

(B)(4). THIS IS A SPONTANEOUS REPORT FROM A CONSUMER, RECEIVED THROUGH (B)(4). A PATIENT, AFTER THE USE OF THE PRODUCT HYALOGYN, EXPERIENCED ALLERGIC REACTION TO EXCIPIENT, VAGINAL BLEEDING AND URINARY TRACT INFECTION IN A CONTEXT OF MEDICATION ERROR. IN FACT, THE PATIENT WAS PRESCRIBED HYALOGYN, BUT SHE HAD A KNOWN ALLERGY TO PROPYLENE GLYCOL THAT IS AN INGREDIENT OF THE PRODUCT. THE CASE HAS BEEN DEEMED AS SERIOUS BY THE COMPANY DUE TO MEDICALLY IMPORTANT CONDITION. THE CASE HAS BEEN DEEMED AS SERIOUS/EXPECTED FOR ALLERGIC REACTION TO EXCIPIENT (PROPYLENE GLYCOL) AS A PROVEN HYPERSENSITIVITY TO A COMPONENT OF THE PRODUCT AND SERIOUS/UNEXPECTED FOR VAGINAL BLEEDING AND URINARY TRACT INFECTION SINCE THEY ARE NOT LISTED IN THE LABEL OF THE PRODUCT. THE CAUSALITY RELATIONSHIP HAS BEEN EVALUATED AS DEFINITE FOR ALLERGIC REACTION TO EXCIPIENT, AS POSSIBLE FOR VAGINAL BLEEDING, SINCE THE EVENT COULD BE LIKELY RELATED TO THE EXTREME VAGINAL DRYNESS OF THE PATIENT, AND AS POSSIBLE FOR URINARY TRACT INFECTION. IN FACT, THERE IS A TEMPORAL RELATIONSHIP BETWEEN THE USE OF HYALOGYN AND THE ONSET OF THE URINARY TRACT INFECTION BUT THERE IS NO SCIENTIFIC GROUNDS TO RELATE THE INFECTION TO THE PRODUCT. THE BATCH NUMBER IS NOT CURRENTLY AVAILABLE FOR AN INVESTIGATION. IF NEW INFORMATION COME TO LIGHT, THE CASE WILL BE RE-EVALUATED. THE CONDITION OF MEDICATION ERROR IS NOT ASSESSABLE.

D

Patient 1

THIS IS A SERIOUS, SPONTANEOUS ADVERSE EVENT REPORTED BY A (B)(6) FEMALE CONSUMER INVOLVING HYALOGYN. IT IS NOT A MEDICAL CONFIRMED CASE. THE PATIENT IS ON NO MEDICATIONS EXCEPT THE ANTIBIOTIC MACRABID WHICH WAS PRESCRIBED AS A RESULT OF THIS ADVERSE EVENT. THE CONSUMERS GYNECOLOGIST RECOMMENDED SHE TRY HYALOGYN FOR EXTREMELY DRY VAGINA. THE CONSUMER PREFERS TO USE ONLY ALL NATURAL PRODUCTS DUE TO ALLERGIES, WHICH IS WHY HER PHYSICIAN RECOMMENDED HYALOGYN. SHE PURCHASED THE PRODUCT AND APPLIED IT INTRAVAGINALLY AS INDICATED IN THE LABELING ON (B)(6) 2019. THE CONSUMER REPORTED THAT SHE INITIALLY EXPERIENCED SOME INITIAL BURNING, DISCOMFORT AND IRRITATION BUT INITIALLY DISMISSED IT DUE TO THE EXTREME DRYNESS OF THE VAGINAL TISSUE. THE PAIN, BURNING AND IRRITATION INCREASED OVER THE NEXT TWO DAYS. SHE ALSO BEGAN TO EXPERIENCE SOME MILD BLEEDING. SHE CONTACTED HER GYNECOLOGIST ON (B)(6) 2019 AND WAS IMMEDIATELY SEEN IN THE CLINIC. THE PHYSICIAN PERFORMED A PHYSICAL EXAM, NOTED THAT THE VAGINA WAS IRRITATED AND RED. A URINE SPECIMEN WAS TESTED AND WAS POSITIVE FOR A URINARY TRACT INFECTION. THE PATIENT DID NOT USE THE PRODUCT AGAIN AND THE PHYSICIAN PRESCRIBED THE ANTIBIOTIC MACROBID FOR A SEVEN DAY REGIMEN. THE PATIENT FINISHED THE ANTIBIOTIC, TAKING HER LAST DOSE ON (B)(6) 2019. SHE WILL RETURN TO THE PHYSICIAN'S OFFICE ON (B)(6) 2019 FOR A FOLLOW-UP EXAM. AT THE TIME OF THIS REPORT THE CONSUMER'S SYMPTOMS HAD IMPROVED. SHE NO LONGER FEELS ANY PAIN, BLEEDING, BURNING OR IRRITATION OF THE VAGINA.